Lantern Pharma Inc. Derivative, Cost of Hedge
Lantern Pharma Inc. (LTRN) reported Derivative, Cost of Hedge of $658.00 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DerivativeCostOfHedge · last filed 2021-05-03
- Lantern Pharma Inc. derivative, cost of hedge for the quarter ending 2021-03-31 was $658.00K, a 2250.00% increase year-over-year.
- Lantern Pharma Inc. derivative, cost of hedge for the quarter ending 2020-03-31 was $28.00K.
| Period end | Derivative, Cost of Hedge 3 month |
|---|---|
| 2021-03-31 | $658.00K 10-Q · filed 2021-05-03 |
| 2020-03-31 | $28.00K 10-Q · filed 2021-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |